JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB273073

Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022]

4

(2 Reviews)

|

(38 Publications)

Human Recombinant Monoclonal SPIKE antibody. Suitable for ELISA, I-ELISA and reacts with Recombinant full length protein - SARS-CoV-2, Recombinant full length protein - SARS-CoV, Recombinant fragment - SARS-CoV-2 samples. Cited in 38 publications. Immunogen corresponding to Cell preparation containing SARS-CoV-2 Spike Glycoprotein S1 protein.

View Alternative Names

2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein

5 Images
ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)
  • ELISA

Supplier Data

ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)

Binding curve of ab273073 to SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag and SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag from HEK293 cells.

ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells at concentrations of 5 μg/ml. A 3-fold serial dilution from 125 ng/ml was performed using ab273073.

For detection, a 1/4000 dilution of HRP-labelled anti-human IgG antibody was used.

ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)
  • ELISA

Supplier Data

ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)

Binding curve of ab273073 to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 of various origin.

ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line), SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) and SARS Coronavirus Spike Glycoprotein (S1), His-Tag (HEK293 cells; blue line) at concentrations of 5 μg/ml. A 3-fold serial dilution from 41.6 ng/ml was performed using ab273073.

For detection, a 1/4000 dilution of HRP-labelled anti-human IgG antibody was used.

Indirect ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)
  • I-ELISA

Lab

Indirect ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)

Indirect ELISA showing primary antibody ab273073 (CR3022, human chimeric) binding to the antigens ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) and ab273068 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active)). Plates were coated with 100ng/well ab272105 or ab273068 and binding of ab273073 assessed in serial dilution from 200ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)
  • ELISA

Unknown

ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)

ELISA using ab273073 and mutant spike proteins. The plate was coated with the mutant spike protein variants (The Native Antigen Company) at 2.5 μg/ml. ab01680 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 1,000 ng/ml. CR3022 (ab01680) exhibited exceptional binding to all mutant spike proteins. RBD WT – wild-type receptor binding domain.

ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)
  • ELISA

Unknown

ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073)

ELISA using ab273073 with UK (B.1.1.7) and South African (B.1.351 (501Y.V2)) mutant spike proteins. The plate was coated with the mutant spike protein variants (The Native Antigen Company) at 2.5 μg/ml. ab01680 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 1,000 ng/ml. CR3022 (ab01680) exhibited exceptional binding to all mutant spike proteins. WT – wild type.

Key facts

Host species

Human

Clonality

Monoclonal

Clone number

CR3022

Isotype

IgG1

Light chain type

kappa

Carrier free

No

Reacts with

SARS-CoV, SARS-CoV-2

Applications

I-ELISA, ELISA

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Epitope

This antibody binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"}, "IELISA" : {"fullname" : "Indirect ELISA", "shortname":"I-ELISA"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Recombinant fragment - SARS-CoV-2": { "ELISA-species-checked": "notRecommended", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "IELISA-species-checked": "testedAndGuaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "<p></p>" }, "Recombinant full length protein - SARS-CoV": { "ELISA-species-checked": "testedAndGuaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "<p></p>", "IELISA-species-checked": "notRecommended", "IELISA-species-dilution-info": "", "IELISA-species-notes": "" }, "Recombinant full length protein - SARS-CoV-2": { "ELISA-species-checked": "testedAndGuaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "<p></p>", "IELISA-species-checked": "notRecommended", "IELISA-species-dilution-info": "", "IELISA-species-notes": "" }, "SARS-CoV": { "ELISA-species-checked": "predicted", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "IELISA-species-checked": "predicted", "IELISA-species-dilution-info": "", "IELISA-species-notes": "" }, "SARS-CoV-2": { "ELISA-species-checked": "predicted", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "IELISA-species-checked": "predicted", "IELISA-species-dilution-info": "", "IELISA-species-notes": "" } } }

Product details

The original CR3022 antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV. This antibody was shown to neutralize SARS-COV in a concerted action with clone CR3014. Presence of both antibodies delivers a blocking action of the SARS-COV RBD-ACE2 interaction, by binding two distinct and functional epitopes (16796401).

CR3022 has been shown to bind with a high affinity to SARS-CoV2 (32416259, 32413276). Structural modelling has confirmed that CR3022 targets a conserved epitope between SARS-CoV and SARS-CoV2 in the RBD domain (32245784, 32065055). Precisely, this antibody binds to the 'open' conformation of the spike protein to the amino acids 318-510 in the S1 domain of the SARS-CoV as well as SARS-CoV-2 strains (32245784, Joyce et al. 2020). The antibody is also able to bind the P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope of clone CR3022 does not overlap with the ACE2 binding site of SARS-COV2 (32065055). Therefore whilst CR3022 can neutralise SARS-COV in in a concerted action with clone CR3014, CR3022 is not believed to independently neutralise SARS-COV2, based on in vitro studies (32226289, 32065055, 32383254, 32416259).

Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody (ab273073) is a Human IgG1 Recombinant version of CR3022 for research use only. CR3022 is also available as a chimeric rabbit antibody (ab273074).

Applications overview

Tick: Tested and Guaranteed to work X: Will not work —: No data

<img src="https://www.abcam.com/ps/Products/273/ab273073/Images/ab273073-394507-applications-overview.jpg" height="125" width="766">

ab273073 was developed to have a human IgG1 isotype.
Other isotypes of clone CR3022 available:
ab278112 – human IgA
ab278111 – human IgM
ab273074 – rabbit IgG
ab273886 – rat IgG2a

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.02% Proclin 300 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The SARS-CoV-2 Spike Glycoprotein S1 also known as the G10 spike or glycoprotein spike plays an important role in allowing the virus to attach and enter host cells. This protein with a mass of approximately 180 kDa is located on the surface of the virus and forms the outer spikes observed in coronaviruses. Expression of the spike glycoprotein is in virus-infected cells where it facilitates the interaction with host cell receptors. The S1 subunit includes a receptor-binding domain that specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptors initiating the infection process.
Biological function summary

The spike glycoprotein S1 mediates the fusion of the viral and cellular membranes which is necessary for viral entry. It forms part of a larger trimeric complex comprising S1 and S2 subunits. This complex undergoes conformational changes that drive the membrane fusion process. The glycoprotein contains multiple glycosylation sites which help shield the virus from the host immune response. The proper function and presentation of this glycoprotein are critical for efficient viral spread and infection establishment.

Pathways

The spike glycoprotein S1 is integral to the viral infection pathway and host immune evasion. It interacts with the renin-angiotensin system by binding to the ACE2 receptor disrupting normal receptor activity. This interaction not only facilitates viral entry but also impacts the homeostatic functions typically mediated by ACE2 which include blood pressure regulation. Additionally the spike protein is involved in downstream activation of immune signaling pathways including those related to inflammation and cytokine production which may involve proteins such as IL-6.

Infection with the spike glycoprotein S1 is directly related to COVID-19. The binding to ACE2 receptors is linked to the pathology of the disease contributing to respiratory symptoms and in severe cases acute respiratory distress syndrome (ARDS). Through the IL-6 signaling pathway the spike protein is indirectly connected to cytokine release syndrome often observed in severe COVID-19 cases. This connection highlights the importance of targeting this glycoprotein for potential therapeutic interventions and diagnostics such as ELISA SARS-CoV-2 tests and the development of anti-spike antibodies available on platforms like antispark.com for research and clinical purposes.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed : 32142651, PubMed : 32155444, PubMed : 33607086). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed : 34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane (PubMed : 32075877, PubMed : 32221306, PubMed : 34903715, PubMed : 36779763). Alternatively, may use NRP1/NRP2 (PubMed : 33082294, PubMed : 33082293) and integrin as entry receptors (PubMed : 35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed : 33082293). Uses also ASGR1 as an alternative receptor in an ACE2-independent manner (PubMed : 34837059). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed : 32817270).. Spike protein S2. Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed : 32142651) or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.. Spike protein S2'. Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.
See full target information S

Publications (38)

Recent publications for all applications. Explore the full list and refine your search

Immunity & ageing : I & A 22:9 PubMed39994686

2025

Secreted IgM deficiency alters the retinal landscape enhancing neurodegeneration associated with aging.

Applications

Unspecified application

Species

Unspecified reactive species

Sarah E Webster,Sydney M Les,Nico Deleon,Daken M Heck,Naomi L Tsuj,Michael J Clemente,Prentiss Jones,Nichol E Holodick

ACS sensors 10:1407-1418 PubMed39960416

2025

Using Machine Learning and Optical Microscopy Image Analysis of Immunosensors Made on Plasmonic Substrates: Application to Detect the SARS-CoV-2 Virus.

Applications

Unspecified application

Species

Unspecified reactive species

Pedro R A Oiticica,Monara K S C Angelim,Juliana C Soares,Andrey C Soares,José L Proença-Módena,Odemir M Bruno,Osvaldo N Oliveira

Viruses 16: PubMed39205315

2024

Kinetic Landscape of Single Virus-like Particles Highlights the Efficacy of SARS-CoV-2 Internalization.

Applications

Unspecified application

Species

Unspecified reactive species

Aleksandar Atemin,Aneliya Ivanova,Wiley Peppel,Rumen Stamatov,Rodrigo Gallegos,Haley Durden,Sonya Uzunova,Michael D Vershinin,Saveez Saffarian,Stoyno S Stoynov

Nature communications 15:4182 PubMed38755157

2024

Recruitment of plasma cells from IL-21-dependent and IL-21-independent immune reactions to the bone marrow.

Applications

Unspecified application

Species

Unspecified reactive species

Marta Ferreira-Gomes,Yidan Chen,Pawel Durek,Hector Rincon-Arevalo,Frederik Heinrich,Laura Bauer,Franziska Szelinski,Gabriela Maria Guerra,Ana-Luisa Stefanski,Antonia Niedobitek,Annika Wiedemann,Marina Bondareva,Jacob Ritter,Katrin Lehmann,Sebastian Hardt,Christian Hipfl,Sascha Hein,Eberhard Hildt,Mareen Matz,Henrik E Mei,Qingyu Cheng,Van Duc Dang,Mario Witkowski,Andreia C Lino,Andrey Kruglov,Fritz Melchers,Carsten Perka,Eva V Schrezenmeier,Andreas Hutloff,Andreas Radbruch,Thomas Dörner,Mir-Farzin Mashreghi

Communications medicine 4:62 PubMed38570605

2024

Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques.

Applications

Unspecified application

Species

Unspecified reactive species

Mathilde Galhaut,Urban Lundberg,Romain Marlin,Robert Schlegl,Stefan Seidel,Ursula Bartuschka,Jürgen Heindl-Wruss,Francis Relouzat,Sébastien Langlois,Nathalie Dereuddre-Bosquet,Julie Morin,Maxence Galpin-Lebreau,Anne-Sophie Gallouët,Wesley Gros,Thibaut Naninck,Quentin Pascal,Catherine Chapon,Karine Mouchain,Guillaume Fichet,Julien Lemaitre,Mariangela Cavarelli,Vanessa Contreras,Nicolas Legrand,Andreas Meinke,Roger Le Grand

JCI insight 9: PubMed38483534

2024

Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.

Applications

Unspecified application

Species

Unspecified reactive species

Han-Sol Park,Anna Yin,Caelan Barranta,John S Lee,Christopher A Caputo,Jaiprasath Sachithanandham,Maggie Li,Steve Yoon,Ioannis Sitaras,Anne Jedlicka,Yolanda Eby,Malathi Ram,Reinaldo E Fernandez,Owen R Baker,Aarthi G Shenoy,Giselle S Mosnaim,Yuriko Fukuta,Bela Patel,Sonya L Heath,Adam C Levine,Barry R Meisenberg,Emily S Spivak,Shweta Anjan,Moises A Huaman,Janis E Blair,Judith S Currier,James H Paxton,Jonathan M Gerber,Joann R Petrini,Patrick B Broderick,William Rausch,Marie Elena Cordisco,Jean Hammel,Benjamin Greenblatt,Valerie C Cluzet,Daniel Cruser,Kevin Oei,Matthew Abinante,Laura L Hammitt,Catherine G Sutcliffe,Donald N Forthal,Martin S Zand,Edward R Cachay,Jay S Raval,Seble G Kassaye,Christi E Marshall,Anusha Yarava,Karen Lane,Nichol A McBee,Amy L Gawad,Nicky Karlen,Atika Singh,Daniel E Ford,Douglas A Jabs,Lawrence J Appel,David M Shade,Bryan Lau,Stephan Ehrhardt,Sheriza N Baksh,Janna R Shapiro,Jiangda Ou,Yu Bin Na,Maria D Knoll,Elysse Ornelas-Gatdula,Netzahualcoyotl Arroyo-Curras,Thomas J Gniadek,Patrizio Caturegli,Jinke Wu,Nelson Ndahiro,Michael J Betenbaugh,Alyssa Ziman,Daniel F Hanley,Arturo Casadevall,Shmuel Shoham,Evan M Bloch,Kelly A Gebo,Aaron Ar Tobian,Oliver Laeyendecker,Andrew Pekosz,Sabra L Klein,David J Sullivan

New biotechnology 80:27-36 PubMed38128698

2023

Site-directed neutralizing antibodies targeting structural sites on SARS-CoV-2 spike protein.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaofeng Li,Liudmila Kulakova,Kezzia Jones,Eric A Toth,Marina Kirkland Mitchell,Qiana Mendez,Michael P Weiner,Thomas R Fuerst

Cell host & microbe 31:1866-1881.e10 PubMed37944493

2023

Cross-regulation of antibody responses against the SARS-CoV-2 Spike protein and commensal microbiota via molecular mimicry.

Applications

Unspecified application

Species

Unspecified reactive species

Marina Bondareva,Lisa Budzinski,Pawel Durek,Mario Witkowski,Stefan Angermair,Justus Ninnemann,Jakob Kreye,Philine Letz,Marta Ferreira-Gomes,Iaroslav Semin,Gabriela Maria Guerra,S Momsen Reincke,Elisa Sánchez-Sendin,Selin Yilmaz,Toni Sempert,Gitta Anne Heinz,Caroline Tizian,Martin Raftery,Günther Schönrich,Daria Matyushkina,Ivan V Smirnov,Vadim M Govorun,Eva Schrezenmeier,Anna-Luisa Stefanski,Thomas Dörner,Silvia Zocche,Edoardo Viviano,Nele Klement,Katharina Johanna Sehmsdorf,Alexander Lunin,Hyun-Dong Chang,Marina Drutskaya,Liubov Kozlovskaya,Sascha Treskatsch,Andreas Radbruch,Andreas Diefenbach,Harald Prüss,Philipp Enghard,Mir-Farzin Mashreghi,Andrey A Kruglov

BioMed research international 2023:3892370 PubMed37869628

2023

Evaluation of Potential Peptide-Based Inhibitors against SARS-CoV-2 and Variants of Concern.

Applications

Unspecified application

Species

Unspecified reactive species

Hattan Boshah,Faris Samkari,Alexander U Valle-Pérez,Sarah M Alsawaf,Ali H Aldoukhi,Panayiotis Bilalis,Salwa A Alshehri,Hepi H Susapto,Charlotte A E Hauser

Viruses 15: PubMed37766247

2023

Atovaquone and Pibrentasvir Inhibit the SARS-CoV-2 Endoribonuclease and Restrict Infection In Vitro but Not In Vivo.

Applications

Unspecified application

Species

Unspecified reactive species

Troy von Beck,Luis Mena Hernandez,Hongyi Zhou,Katharine Floyd,Mehul S Suthar,Jeffrey Skolnick,Joshy Jacob
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com